Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BSP:PNVL3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.83 Med: 11.32 Max: 28.93
Current: 4.93
During the past 13 years, the highest EV-to-EBITDA of Dimed Distribuidora de Medicamentos was 28.93. The lowest was 4.83. And the median was 11.32.
BSP:PNVL3's EV-to-EBITDA is ranked better than 85.25% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.97
vs BSP:PNVL3: 4.93
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dimed Distribuidora de Medicamentos's PE Ratio (TTM) for today is calculated as:
Dimed Distribuidora de Medicamentos's share price for today is R$11.09.
Dimed Distribuidora de Medicamentos's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0.710.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos EV-to-EBITDA Chart
BSP:PNVL3 vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's EV-to-EBITDA falls into.
Dimed Distribuidora de Medicamentos's current Enterprise Value is R$2,765 Mil.
Dimed Distribuidora de Medicamentos's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$561 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a EV-to-EBITDA of 4.93 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dimed Distribuidora de Medicamentos. This is 56% below median its historical median of 11.32. Over the past decade, Dimed Distribuidora de Medicamentos' EV-to-EBITDA has ranged from 4.83 to 28.93. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #109 out of 739 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Dimed Distribuidora de Medicamentos' EV-to-EBITDA too high?
Dimed Distribuidora de Medicamentos' current EV-to-EBITDA of 4.93 is 56% below median its 10-year median of 11.32. Over the past 10 years, this metric has ranged from a low of 4.83 to a high of 28.93. The Drug Manufacturers industry median EV-to-EBITDA is 12.97. Dimed Distribuidora de Medicamentos' value of 4.93 is 62% below this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #109 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #109 out of 739 companies for EV-to-EBITDA. This places Dimed Distribuidora de Medicamentos in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.97. Dimed Distribuidora de Medicamentos' value of 4.93 is 62% below this benchmark. Historically, Dimed Distribuidora de Medicamentos' own EV-to-EBITDA has ranged from 4.83 to 28.93 over the past decade. While the company's 10-year median is 11.32 vs. the industry median of 12.97, Dimed Distribuidora de Medicamentos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.97, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current EV-to-EBITDA of 4.93 is 62% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Dimed Distribuidora de Medicamentos. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current EV-to-EBITDA is 4.93, which is 56% below median its own 10-year median of 11.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.20, compared to a current price of R$11.09 — trading 16% below its estimated fair value. The current EV-to-EBITDA is 4.93, which is 56% below median its 10-year median of 11.32 and 62% below the Drug Manufacturers industry median of 12.97. Dimed Distribuidora de Medicamentos' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current EV-to-EBITDA is 4.93 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.09 is trading 16% below its estimated GF Value™ of R$13.20.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
EV-to-EBITDA: 4.93 (56% below median its 10-year median of 11.32)
GF Value™: R$13.20 vs. price of R$11.09 (16% below fair value)
Industry Position: 62% below the Drug Manufacturers median (#109 of 739)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
88GF Score
Get the complete analysis for BSP:PNVL3
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
